Senescence: A gradual path to mortality
Many of the features associated with senescence appear steadily over time before cells stop dividing.
- Laboratory of Genetics and Genomics, National Institute on Aging, National Institutes of Health, United States
In 1961, Hayflick and Moorhead discovered that human fibroblast cells cultured in the laboratory could only divide a limited number of times, after which they stopped multiplying but remained metabolically active (Hayflick and Moorhead, 1961). It did not matter how the cells were cultured – whether they were repeatedly transferred, or ‘passaged’, into a fresh environment, or if their growth was interrupted by episodes of freezing – the number of divisions they could make was always finite. This state was termed replicative senescence and was found to occur in a range of cell types.
Further research revealed that senescence is caused by the shortening of caps, or ‘telomeres’, on the end of chromosomes (Bodnar et al., 1998). Every time a cell divides, its telomeres shrink until they reach a critical length that stops the cell from multiplying. Once senescent, cells display unique features such as expressing certain proteins, releasing inflammatory molecules, and loosening tightly packed regions of DNA known as heterochromatin (Hernandez-Segura et al., 2018). New evidence showed that senescence is induced by cell stress as well as successive divisions, and that the number of senescent cells increases as tissues age (van Deursen, 2014).
Despite almost 60 years of research, many questions still remain about senescence; for instance, what happens to cells as they transition in to the senescent state? How does their metabolism change during this shift, and do they take on a new cell identity? Now, in eLife, David Botstein, David Hendrickson and colleagues from Calico Life Sciences – including Michelle Chan as first author – report the results of experiments that exquisitely profile the roadmap cells take on their path to senescence (Chan et al., 2022).
The team used a new experimental design to survey the entire genome and repertoire of RNAs, proteins, and metabolites present in fibroblasts cultured in the laboratory. These patterns were traced over time as the cells grew until they stopped dividing. Chan et al. then used a range of control conditions to pinpoint which changes were specific to replicative senescence. This included repeating the experiment on cells growing at a similar density to senescent cultures, cells that had only been passaged a few times (and therefore unlikely to be senescent), cells that never become senescent, and cells made senescent by radiation-induced stress.
To begin with, Chan et al. measured the level of unique RNAs in single cells to investigate how the genes that fibroblasts expressed changed over time. The data revealed that RNAs known to be expressed in fully senescent cells progressively accumulate throughout the cell cycle. This suggests that senescent cells in vivo may be slowly amassing these features, but not yet expressing the classic biomarkers associated with the end-point of senescence, such as the beta-galactosidase enzyme. This may explain why previous studies found less than 20% of cells in old tissues exhibited these biomarkers, which has led researchers to question the role of senescence in aging (Biran et al., 2017; Idda et al., 2020). Chan et al. also found cells that had experienced replicative senescence (but not senescence induced by radiation) expressed genes related to a subtype of epithelial-to-mesenchymal transition (EMT). This process, which sees epithelial cells lining surfaces of the body lose their identity and become mesenchymal, is common in development and cancer.
Further experiments revealed that cells change how they use and generate energy as they progress towards replicative senescence. Similar metabolic changes have also been observed in models of EMT, further validating the connection between replicative senescence and this transition. Chan et al. discovered that the protein complex YAP1/TEAD1 and its target, the growth factor protein TGFβ2, drove this shift in energy. Applying a drug that stops YAP1 and TEAD1 from assembling (Wang et al., 2016) reduced the expression of signatures associated with mesenchymal cells and senescence.
Finally, Chan et al. identified another signature of replicative stress: the increased expression of Nicotinamide N-methyltransferase (NNMT). This enzyme catalyzes chemical reactions that ultimately prevent certain proteins from condensing DNA. It is possible that by reducing the activity of these proteins, NNMT is able to open up closed regions of the genome, which may explain the reported loss of heterochromatin in senescent cells (Yang and Sen, 2018).
The findings of Chan et al. suggest that cells gradually acquire a number of changes on the path to replicative senescence: they express different genes, rewire their metabolic reactions and take on a new identity similar to mesenchymal cells (Figure 1). Previous studies have shown that removing senescent cells can increase the health- and life-span of mice (Di Micco et al., 2021). Therefore, interventions that target these early changes could help improve the wellbeing of individuals by stopping the cascade of events that lead to replicative senescence.
Figure 1
The journey to replicative senescence.
Healthy cells cultured in the laboratory (left) will undergo continuous rounds of division until they reach a state of growth arrest called replicative senescence (right; shown in blue). To begin with (early and early-middle stages), cells express factors associated with cell cycle progression and growth as well as proteins that maintain chromatin stability. As they progress towards replicative senescence (middle-late stage), they undergo an epithelial-to-mesenchymal transition (EMT) and change their cell identity: this transition is driven by the growth factor protein TGFβ2 and the protein complex YAP1/TEAD1. As cells near replicative senescence (late stage), they exhibit a pro-inflammatory phenotype and secrete cytokines, in addition to expressing a beta-galactosidase enzyme which is detected by a reaction that turns cells blue.
Image credit: Figure created using BioRender.
References
-
Cellular senescence in ageing: from mechanisms to therapeutic opportunitiesNature Reviews Molecular Cell Biology 22:75–95.https://doi.org/10.1038/s41580-020-00314-w
-
The serial cultivation of human diploid cell strainsExperimental Cell Research 25:585–621.https://doi.org/10.1016/0014-4827(61)90192-6
-
Hallmarks of cellular senescenceTrends in Cell Biology 28:436–453.https://doi.org/10.1016/j.tcb.2018.02.001
-
Verteporfin inhibits YAP function through up-regulating 14-3-3sigma sequestering YAP in the cytoplasmAmerican Journal of Cancer Research 6:27–37.
Article and author information
Author details
Publication history
- Version of Record published: March 18, 2022 (version 1)
Copyright
© 2022, Yang and Sen
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,848
- Page views
-
- 222
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Senescence: A gradual path to mortality
eLife 11:e77749.
https://doi.org/10.7554/eLife.77749
Further reading
-
- Chromosomes and Gene Expression
Promyelocytic leukemia Nuclear Bodies (PML NBs) are nuclear membrane-less organelles physically associated with chromatin underscoring their crucial role in genome function. The H3.3 histone chaperone complex HIRA accumulates in PML NBs upon senescence, viral infection or IFN-I treatment in primary cells. Yet, the molecular mechanisms of this partitioning and its function in regulating histone dynamics have remained elusive. By using specific approaches, we identify intermolecular SUMO-SIM interactions as an essential mechanism for HIRA recruitment in PML NBs. Hence, we describe a role of PML NBs as nuclear depot centers to regulate HIRA distribution in the nucleus, dependent both on SP100 and DAXX/H3.3 levels. Upon IFN-I stimulation, PML is required for interferon-stimulated genes (ISGs) transcription and PML NBs become juxtaposed to ISGs loci at late time points of IFN-I treatment. HIRA and PML are necessary for the prolonged H3.3 deposition at the transcriptional end sites of ISGs, well beyond the peak of transcription. Though, HIRA accumulation in PML NBs is dispensable for H3.3 deposition on ISGs. We thus uncover a dual function for PML/PML NBs, as buffering centers modulating the nuclear distribution of HIRA, and as chromosomal hubs regulating ISGs transcription and thus HIRA-mediated H3.3 deposition at ISGs upon inflammatory response.
-
- Cell Biology
- Chromosomes and Gene Expression
The shape and size of the human cell nucleus is highly variable amongst cell types and tissues. Changes in nuclear morphology are associated with disease, including cancer, as well as with premature and normal aging. Despite the very fundamental nature of nuclear morphology, the cellular factors that determine nuclear shape and size are not well understood. To identify regulators of nuclear architecture in a systematic and unbiased fashion, we performed a high-throughput imaging-based siRNA screen targeting 867 nuclear proteins including chromatin-associated proteins, epigenetic regulators, and nuclear envelope components. Using multiple morphometric parameters and eliminating cell cycle effectors, we identified a set of novel determinants of nuclear size and shape. Interestingly, most identified factors altered nuclear morphology without affecting the levels of lamin proteins, which are known prominent regulators of nuclear shape. In contrast, a major group of nuclear shape regulators were modifiers of repressive heterochromatin. Biochemical and molecular analysis uncovered a direct physical interaction of histone H3 with lamin A mediated via combinatorial histone modifications. Furthermore, disease-causing lamin A mutations that result in disruption of nuclear shape inhibited lamin A-histone H3 interactions. Finally, oncogenic histone H3.3 mutants defective for H3K27 methylation resulted in nuclear morphology abnormalities. Altogether, our results represent a systematic exploration of cellular factors involved in determining nuclear morphology and they identify the interaction of lamin A with histone H3 as an important contributor to nuclear morphology in human cells.
